Cephalosporin-resistant gonorrhea in North America

JAMA

Volumn 309, Issue 2, 2013, Pages 185-187

  Kirkcaldy, Robert D ^a   Bolan, Gail A ^a   Wasserheit, Judith N ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; CEPHALOSPORIN; DOXYCYCLINE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOLITHROMYCIN; SULFONAMIDE; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GONORRHEA; HUMAN; INCIDENCE; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NORTH AMERICA; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SINGLE DRUG DOSE;

EID: 84872067549     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.205107     Document Type: Editorial

References (16)

1. Global incidence and prevalence of selected curable sexually transmitted infections: 2008. World Health Organization. http://www.who.int/ reproductivehealth/publications/rtis/2008-STI-estimates.pdf. Accessed December 17, 2012.
2. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2011. Atlanta, GA: US Dept of Health & Human Services; 2012.
3. Weinstock HS, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36(1):6-10.
4. Braunstein SL, Ingabire CM, Kestelyn E, et al. High human immunodeficiency virus incidence in a cohort of Rwandan female sex workers. Sex Transm Dis. 2011;38(5):385-394.
5. Centers for Disease Control and Prevention (CDC). Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep. 2007;56(14):332-336.
6. Kirkcaldy RD, Ballard RC, Dowell D. Gonococcal resistance: are cephalosporins next? Curr Infect Dis Rep. 2011;13(2):196-204.
7. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. Highlevel cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012;56(3):1273-1280.
8. Centers for Disease Control and Prevention (CDC). Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep. 2012;61(31):590-594.
9. Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA. 2013;309(2):163-170.
10. Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis. 2007;44(suppl 3):S84-S101.
11. Bignell C, Fitzgerald M; Guideline Development Group; British Association for Sexual Health and HIV UK. UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS. 2011;22(10):541-547.
12. Bignell C, Unemo M. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. International Union against Sexually Transmitted Infections. http://www.iusti.org/regions/Europe/pdf/2012/Gonorrhoea- 2012.pdf. Accessed December 17, 2012.
13. Important notice: public health information update on the treatment for gonococcal infection. Public Health Agency of Canada. http://www.phac-aspc.gc. ca/std-mts/sti-its/alert/2011/alert-gono-eng.php. Accessed December 17, 2012.
14. Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother. 2010;65(10):2141-2148.
15. Cephalosporin-resistant Neisseria gonorrhoeae public health response plan. Centers for Disease Control and Prevention. http://www.cdc.gov/std/ treatment/Ceph-R-ResponsePlanJuly30-2012.pdf. Accessed December 17, 2012.
16. Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med. 2012;366(6):485-487.